Miriam González Pardo

Detail-oriented team player with strong organizational skills. Ability to handle multiple projects simultaneously with a high degree of accuracy. Hardworking and passionate job seeker with strong organizational skills eager to secure entry-level Medical Director/ Senior Medical Director, Clinical Research, Hematology position. Ready to help team achieve company goals. Organized and dependable candidate successful at managing multiple priorities with a positive attitude. Willingness to take on added responsibilities to meet team goals.

• EDUCATIONAL BACKGROUND
• Graduated in Medicine and Surgery
• Universidad Complutense de Madrid, 2002-2009
• Internship in Hematology and Hemotherapy, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Spain
• May 2014
• EXPERIENCE:
• Hematology physician at Hospital Universitario de La Princesa (National Health System, Madrid Public Health System), Spain
• June 2014- January 2016
• Member of the team responsible for the JACIE certification to the autologous and allogenic transplant program of the Hospital Universitario de La Princesa, Madrid, 2015
• Medical Affairs Manager, Hematology M Medical Department, Janssen-Cilag, Madrid-Spain
• January 2016- today
• CLINICAL TRIALS
• Protocol 16201 (OMB110913)
• Sub investigator
• Open phase Ib / II trial to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine monotherapy in patients with relapsed chronic lymphocytic leukemia
• IP: Javier Loscertales
• Sponsor: Phamanet
• Protocol OMB115991
• Sub investigator
• Phase II, multicenter study to investigate the safety and efficacy of the combination of bendamustine and ofatumumab in patients with chronic lymphocytic leukemia untreated or relapsed
• IP: Javier Loscertales
• Sponsor: GSK
• Protocol CC- 486-AML-001
• Sub investigator
• Phase 3 study, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of oral Azacitidine plus best supportive care versus best supportive care as maintenance therapy in patients with acute myeloid leukemia in complete remission not transplant candidates
• IP: Ángela Figuera
• Sponsor: Celgene
• Protocol MDA-AML-2017-05: Janssen SRP
• Decitabine in Acute Myeloid Leukemia
• A Multicenter Retrospective Study
• IP: Adolfo de la Fuente
• Sponsor: HEMOINFO
• Protocol GEM‐DAR‐2018‐01: Janssen SRP
• Treatment with Daratumumab in relapsed / refractory Multiple Myeloma patients in clinical care practice in Catalonia
• A retrospective study
• IP: Laura Rosiñol
• Sponsor: GEMMAC
• Protocol GEM2017FIT: Janssen SRP
• Induction therapy with bortezomib, melphalan, and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) vs
• Carfilzomib, lenalidomide, and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: a phase III, multicenter, randomized clinical trial for elderly patients, between 65 and 80 years of age, with good general condition and newly diagnosed multiple myeloma
• IP: María Victoria Mateos/J
• San Miguel
• Sponsor: PETHEMA
• Protocol GEM- SELIBORDARA: Janssen SRP
• Phase 2, multicenter, open-label trial of selinexor (KPT-330), bortezomib, and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with relapsed and/or refractory multiple myeloma
• IP: María Victoria Mateos/J
• San Miguel
• Sponsor: PETHEMA
• Protocol GEM-IBERDARAX: Janssen SRP
• Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients
• IP: María Victoria Mateos/J
• San Miguel
• Sponsor: PETHEMA
• Protocol 54767414MMY4015: Sponsor's Responsible Medical Officer
• Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma
• Spain RWE data
• GeminiS study
• Sponsor: Janssen
• Protocol 54767414MMY4024: Sponsor's Responsible Medical Officer
• Observational study to describe the repercussion of monoclonal antibodies as first-line treatment versus other standard regimens in newly diagnosed multiple myeloma patients who are ineligible for autologous stem-cell transplantation
• Spain RWE data
• Carinae study
• Sponsor: Janssen.

· Protocol 16201 (OMB110913). Sub investigator. Open phase Ib / II trial to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine monotherapy in patients with relapsed chronic lymphocytic leukemia. IP: Javier Loscertales. Sponsor: Phamanet.

• Protocol OMB115991. Sub investigator. Phase II, multicenter study to investigate the safety and efficacy of the combination of bendamustine and ofatumumab in patients with chronic lymphocytic leukemia untreated or relapsed. IP: Javier Loscertales. Sponsor: GSK.

· Protocol CC- 486-AML-001. Sub investigator. Phase 3 study, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of oral Azacitidine plus best supportive care versus best supportive care as maintenance therapy in patients with acute myeloid leukemia in complete remission not transplant candidates. IP: Ángela Figuera. Sponsor: Celgene.

• Protocol MDA-AML-2017-05: Janssen SRP. Decitabine in Acute Myeloid Leukemia. A Multicenter Retrospective Study. IP: Adolfo de la Fuente. Sponsor: HEMOINFO.

· Protocol GEM‐DAR‐2018‐01: Janssen SRP. Treatment with Daratumumab in relapsed / refractory Multiple Myeloma patients in clinical care practice in Catalonia. A retrospective study. IP: Laura Rosiñol. Sponsor: GEMMAC

• Protocol GEM2017FIT: Janssen SRP. Induction therapy with bortezomib, melphalan, and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) vs. carfilzomib, lenalidomide, and dexamethasone (KRd) plus/minus daratumumab, 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: a phase III, multicenter, randomized clinical trial for elderly patients, between 65 and 80 years of age, with good general condition and newly diagnosed multiple myeloma. IP: María Victoria Mateos/J. San Miguel. Sponsor: PETHEMA.

• Protocol GEM- SELIBORDARA: Janssen SRP. Phase 2, multicenter, open-label trial of selinexor (KPT-330), bortezomib, and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with relapsed and/or refractory multiple myeloma. IP: María Victoria Mateos/J. San Miguel. Sponsor: PETHEMA.

• Protocol GEM-IBERDARAX: Janssen SRP. Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment regimens in transplant ineligible newly diagnosed patients. IP: María Victoria Mateos/J. San Miguel. Sponsor: PETHEMA.

• Protocol 54767414MMY4015: Sponsor's Responsible Medical Officer. Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Spain RWE data. GeminiS study. Sponsor: Janssen.

• Protocol 54767414MMY4024: Sponsor's Responsible Medical Officer. Observational study to describe the repercussion of monoclonal antibodies as first-line treatment versus other standard regimens in newly diagnosed multiple myeloma patients who are ineligible for autologous stem-cell transplantation. Spain RWE data. Carinae study. Sponsor: Janssen.

Poster:

• Plasma exchange therapy in patients with optic neuritis: experience at the University Hospital of La Princesa. Cuadrado M, Quereda B, Acedo N, Fernández-Arandojo C, González-Pardo M, Villanueva MJ; García-León N, Martínez S, Royg M, Fernández-Villalta MJ, Alegre A, Aguado B. Haematology Service of the University Hospital La Princesa. Madrid. SEHH National Congress 2011.

• Immunochemotherapy in patients with CLL over 70 years: experience at the University Hospital of La Princesa. Quereda B, Acedo N, Cuadrado M, Martínez S, Roig M, García-León N, González-Pardo M, Fernández-Arandojo, Villanueva MJ, Alegre A, Loscertales J. Haematology Service of the University Hospital La Princesa Madrid. SEHH National Congress 2011.

• Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience. González -Pardo M; Fernandez-Arandojo C; Cannata J; Aguado B; García-Noblejas A; Arranz R. DOI: 10.3252/pso.es.56sehh.2014.

• Extracorporeal photopheresis (ECP) as second line treatment for refractory graft versus host disease (GVHD): preliminary single center experience. Aguado B; Fernández-Arandojo C; González-Pardo M; Acuña E; Guijarro S; Vicuña I; Alegre A. DOI: 10.3252/pso.es.56sehh.2014.

• Retrospective analysis of the use of filgrastim and lenograstim for the mobilization of peripheral blood hematopoietic progenitors (PHSP) in patients with multiple myeloma (MM): Effectiveness and impact on engraftment, HU La Princesa experience. González-Pardo M; Aguado B; De Paz Y; Lorenzo A; Veramendi Susie; Vicuña I; Alegre A. DOI: 10.3252/pso.es.56sehh.2014.

• Ríos-Tamayo R, Arnao M, Domingo A, Sánchez JL, Soler JA, García A, Garzón S, López A, Hevia H, González-Pardo M, Leiva C, de la Rubia J, Mateos MV. Observational study to describe the impact of treatment combinations with Daratumumab versus other alternative regimens in patients with relapsed / refractory multiple myeloma. Real world evidence data in Spain. 17th International Myeloma Workshop (IMW); September 12-15; 2019; Boston, MA, USA. Poster FP-160.

• Ríos-Tamayo R, Arnao M, Domingo A, Sánchez JL, Soler JA, García A, Garzón S, López A, Hevia H, González-Pardo M, Leiva C, de la Rubia J, Mateos MV. Incorporación de daratumumab en combinación al panorama terapéutico de pacientes con mieloma múltiple en recaída: resultados de práctica clínica diaria en España. Estudio GeminiS. LXI Congreso Nacional de Hematología y Hemoterapia (SEHH); 24-26 octubre; 2019; Valencia, ES. Poster PO-022. DOI: 10.3252/pso.es.61SEHH-35SETH.2019.

Publications:

• New drugs in the treatment of Multiple Myeloma. Alegre A, Aguado B, González-Pardo M, Vicuña I. Libro de presentaciones IX Congreso Anual AMHH. Madrid, Abril 2014.

• Extracorporeal photopheresis (ECP) as second line treatment for refractory graft versus host disease (GVHD): preliminary single center experience. Aguado B. Fernández-Arandojo C, González-Pardo M, Acuña E, Guijarro S, Vicuña I, Alegre A. Servicio de Hematología Hospital Universitario de La Princesa. Abstract Book 19th Congress of the European Hematology Association. Milan, June 2014.

• Peripheral T/NK-Cell Lymphomas: Survival with Current Treatment Strategies. La Princesa University Hospital Single Experience. González-Pardo M, Fernández-Arandojo C, Cannata J, Aguado B, García-Noblejas A, Alegre A, Arranz R. December 6, 2014; Blood: 124 (21).

• Comparison of Assesment of Imaging Response with Magnetic Resonance (MR) and 18fdg-PET/TC in Multiple Myeloma (MM). Single Centre Experience. Alegre A, Aguado B, González-Pardo M, Acuña E, Arriero A, Aragonés M, Del Campo L, Llorente S, Ocón E, Gómez-León N. December 6, 2014; Blood: 124 (21).

• Allogeneic hematopoietic stem cell transplant. González-Pardo M, Veramendi S, Arriero A, Aguado B, Vicuña I. The resident physician in hematology and hemotherapy manual. Editores Médicos S.A. EDIMSA. Spanish Society of Hematology and Hemotherapy.

• Autologous hematopoietic stem cell transplant. Aguado Bueno B, González-Pardo M, Gómez-García de Soria V, Alegre A. Terapia en Oncohematología IV edición. Fernández-Rañada JM, Alegre A.

• Treatment of Multiple Myeloma. Alegre Amor A, Aguado Bueno B, Vicuña Andrés I, Arriero García A, González-Pardo M. Terapia en Oncohematología IV edición. Fernández-Rañada JM, Alegre A.

• Allogeneic hematopoietic stem cell transplant from related donor and haploidentical donor. Figuera Álvarez A, González-Pardo M, Guijarro Montoro S. Terapia en Oncohematología IV edición. Fernández-Rañada JM, Alegre A.

• Allogeneic hematopoietic stem cell transplantant from unrelated donor. De la Cámara Llanza R, González-Pardo M, Figuera Álvarez A. Terapia en Oncohematología IV edición. Fernández-Rañada JM, Alegre A.

• Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication. Arteche-López A, Kreutzman A, Alegre A, Sanz Martín P, Aguado B, González-Pardo M, Espiño M, Villar LM, García Belmonte D, de la Cámara R, Muñoz-Calleja C. Bone Marrow Transplant. 2017 Jun;52(6):832-838.

• De Arriba de la Fuente F, Durán MS, Álvarez MA, Sanromán IL, Dios AM, Ríos Tamayo R, García R, González MS, Prieto E, Bárez A, Escalante F, Tejedor A, Ballesteros M, Cabañas V, Capote FJ, Couto C, Garzón S, González-Pardo M, Mateos Manteca MV. Subcutaneous bortezomib in newly diagnosed multiple myeloma patients non-transplant eligible: Retrospective evaluation. Semin Hematol. 2018 Oct;55(4):189-196.

• de Arriba de la Fuente, F.; Hernández Garcia, M. T.; Soler Campos, J. A.; Susana, H. R.; Moreno Belmonte, M. J.; González-Pardo, M.; Gironella Mesa, M.; Casanova Espinosa, M. PB2001: A look into the real world: picture of newly diagnosed multiple myeloma transplant ineligible treated patients in the frontline setting. carinae study. HemaSphere: June 2022 - Volume 6 - Issue - p 1872-1873 doi: 10.1097/01.HS9.0000850836.59443.65

· Member of the Spanish Society of Hematology and Hemotherapy (SEHH).

· Member of the European Hematology Association (EHA).

• Certified [Job Title], [Company Name] - [Timeframe]